IN8bio (INAB) Stock Price, News & Analysis

Company Overview

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.

Key Stats

• Today's Range: $1.53 to $1.73
• 50-Day Range: $1.35 to $2.00
• 52-Week Range: $1.17 to $4.17
• Volume: 108,746 shs
• Average Volume: 65,938 shs
• Market Capitalization: $15.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

IN8bio Stock Analysis - MarketRank™

IN8bio scored higher than 77% of companies evaluated by MarketBeat, and ranked 177th out of 868 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

IN8bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

IN8bio has a consensus price target of $4.00, representing about 156.4% upside from its current price of $1.56.

Amount of Analyst Coverage

IN8bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IN8bio are expected to grow in the coming year, from ($1.53) to ($1.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IN8bio is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IN8bio is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IN8bio has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.92% of the float of IN8bio has been sold short.

Short Interest Ratio / Days to Cover

IN8bio has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IN8bio has recently decreased by 34.12%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IN8bio does not currently pay a dividend.

Dividend Growth

IN8bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.68

News Sentiment

IN8bio has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for IN8bio this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for INAB on MarketBeat in the last 30 days.

MarketBeat Follows

6 people have added IN8bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IN8bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.50% of the stock of IN8bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

92.05% of the stock of IN8bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 6/02/2026
• Corporate presentation: 6/02/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INAB
• CIK: 1740279
• Web: www.in8bio.com
• Phone: 646-600-6438
• Fax: N/A
• Employees: 20
• Year Founded: 2016

Price Target and Rating

• Average Price Target for IN8bio: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +156.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -96.39%
• Return on Assets: -80.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.50
• Quick Ratio: 10.50

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.82 per share
• Price / Book: 0.55

Miscellaneous

• Outstanding Shares: 9,850,000
• Free Float: 8,419,000
• Market Cap: $15.37 million
• Optionable: Not Optionable
• Beta: 0.19